SignalChem Lifesciences Corporation   Report issue

For profit Phase 2
Founded: Richmond Canada (2004)

Organization Overview

First Clinical Trial
2019
NCT03990454
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

SignalChem Lifesciences Corporation

Active Ingredients

Drugs in Phase 2 Trials (2)

pembrolizumab (keytruda) (1 trial)

slc-391 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2